Pancreatic Ductal Carcinoma Market

• According to DelveInsight’s estimates, 90 out of 100, i.e., 90%, of all pancreatic cancers are Pancreatic Ductal Adenocarcinoma (PDAC). The total number of incident cases of pancreatic ductal adenocarcinoma in the 7MM (the US, EU4, the UK, and Japan) is expected to rise during the study period from 2020 to 2034.
• According to the findings, pancreatic cancer is currently the third leading cause of cancer-related death in the United States, with an estimated over 60,000 new diagnoses in the United States each year.
• The United States accounts for the largest market size of pancreatic ductal adenocarcinoma, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• Quantitatively Pancreatic Cancer pipeline seems to be quite strong, however clinical trials face difficulties in patient recruitment due to the disease's aggressive nature and late-stage diagnosis.
• In May 2024, Oncolytics Biotech entered a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR). The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma as part of GCAR’s anticipated master protocol for metastatic pancreatic cancer.
• Major pharmaceutical and biotech companies, including Candel Therapeutics, Panbela Therapeutics, FibroGen, Oncolytics Biotech, and VCN Bioscience, are actively engaged in the PDAC market.

DelveInsight's “Pancreatic Ductal Adenocarcinoma – Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Pancreatic Ductal Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Ductal Adenocarcinoma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Pancreatic Ductal Adenocarcinoma market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Pancreatic Ductal Adenocarcinoma market size from 2020 to 2034. The report also covers current Pancreatic Ductal Adenocarcinoma treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Pancreatic Ductal Adenocarcinoma Understanding and Treatment Algorithm

Pancreatic Ductal Adenocarcinoma Overview, Country-Specific Treatment Guidelines and Diagnosis

• Pancreatic ductal adenocarcinoma is the most common malignant neoplasm of the pancreas. It is the 9th most common form of solid cancer and is diagnosed in advanced stages in most of the cases. There are no curative options except for surgical therapy in the early stages. As a resection can be offered to only 15–20% of patients, early and precise diagnostic modalities could have a major impact on the improvement of the prognosis of pancreatic ductal adenocarcinoma patients.
• Pancreatic ductal adenocarcinoma research has made some major progress in the identification of genetic and epigenetic changes that are responsible for PDAC tumorigenesis. Several mutated oncogenes or tumor suppressor genes (i.e., KRAS, TP53, CDKN2A, and SMAD4) were identified as playing a major role pancreatic ductal adenocarcinoma. 
• According to the findings approximately 10% to 15% of pancreatic ductal adenocarcinoma cases are due to inherited mutations. High-risk individuals (HRIs) with a significantly increased risk for pancreatic ductal adenocarcinoma can be identified and offered surveillance.
• The most commonly reported symptoms are fatigue, weight loss, anorexia, and abdominal or back pain. Tumors that arise in the pancreatic head and neck may be associated with pruritis and jaundice from biliary obstruction, whereas tumors in the body and tail of the gland more commonly present with pain.
• EUS-FNA is considered the most effective test for the definitive diagnosis of pancreatic ductal adenocarcinoma, as it can diagnose histopathology. The sensitivity and specificity rates of EUS-FNA for the diagnosis of pancreatic ductal adenocarcinoma were 85–92% and 96–98%, respectively, in four meta-analyses.
• Pancreatic cancer has a very poor prognosis with a median survival of approximately 10 to 12 months with treatment and 5 to 6 months without treatment due to the advanced stage of diagnosis for many patients and the low percentage of patients eligible for surgical resection. The current standard of care for first-line therapy is FOLFIRONOX (a combination of 5-fluorouracil [5-FU], leucovorin, irinotecan, and oxaliplatin) or gemcitabine plus albumin-bound nab-paclitaxel.

Further details related to country-based variations in diagnosis are provided in the report

Pancreatic Ductal Adenocarcinoma Treatment

Treatment options for resectable or borderline resectable pancreatic cancer include the following:

• Neoadjuvant therapy: Neoadjuvant chemotherapy with or without chemoradiation therapy.
• Surgery: Radical pancreatic resection including:
• Whipple procedure (pancreaticoduodenal resection).
• Total pancreatectomy when necessary for adequate margins.
• Distal pancreatectomy for tumors of the body and tail of the pancreas.
• Postoperative chemotherapy: Radical pancreatic resection followed by chemotherapy.
• Postoperative chemoradiation therapy: Radical pancreatic resection followed by fluorouracil (5-FU) chemotherapy and radiation therapy.
• Preoperative chemotherapy and/or radiation therapy
• Alternative radiation techniques

Pancreatic Ductal Adenocarcinoma Epidemiology

The Pancreatic Ductal Adenocarcinoma epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Pancreatic Ductal Adenocarcinoma epidemiology is segmented with detailed insights into Total Incident Cases of Pancreatic Ductal Adenocarcinoma, Gender specific cases of Pancreatic Ductal Adenocarcinoma, Age-group specific cases of Pancreatic Ductal Adenocarcinoma, Stage- specific cases of Pancreatic Ductal Adenocarcinoma in the 7MM [2020–2034, and Total Treated cases of Pancreatic Ductal Adenocarcinoma [2020–2034].

• As per DelveInsight's estimates, the total incident cases of pancreatic ductal adenocarcinoma in the 7 major markets was around 165,000 cases in 2023. 
• In the United States, the incident cases of pancreatic ductal adenocarcinoma were around 58,000 cases in 2023. 
• The risk of developing pancreatic ductal adenocarcinoma increases with age, with most cases diagnosed in individuals aged 65 and older.

Pancreatic Ductal Adenocarcinoma Drug Chapters

The drug chapter segment of the Pancreatic Ductal Adenocarcinoma report encloses a detailed analysis of Pancreatic Ductal Adenocarcinoma marketed drugs. It also deep dives into the Pancreatic Ductal Adenocarcinoma pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Marketed Drugs

LYNPARZA (olaparib): AstraZeneca

LYNPARZA is used for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

VITRAKVI (larotrectinib): Bayer and Loxo Oncology

VITRAKVI is a kinase inhibitor used to treat adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known resistance mutation. It is indicated for cases where the tumors are metastatic or cannot be surgically removed without severe morbidity, and where no satisfactory alternative treatments exist, or the tumors have progressed following previous treatments.

Note: Detailed current therapies assessment will be provided in the full report of Pancreatic Ductal Adenocarcinoma.

Emerging Drugs

CAN-2409: Candel Therapeutics

CAN-2409 stands out as an off-the-shelf, pan-solid tumor therapy that harnesses an individualized anti-cancer immune response. The innovative therapy is locally administered and combined with an oral prodrug, designed to induce a potent CD8+ cytotoxic T cell response. This mechanism positions CAN-2409 as a compelling option for various solid tumors, leveraging the immune system's ability to target and eliminate cancer cells.

In December 2023, Candel Therapeutics announced that the FDA granted fast track designation for CAN-2409 plus valacyclovir for the treatment of patients with pancreatic ductal adenocarcinoma to improve overall survival.

SBP-101: Panbela Therapeutics

SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Currently, the company is investigating the drug in Phase III for first-line metastatic pancreatic cancer for which interim analysis is expected in 2024.

Note: Detailed emerging therapies assessment will be provided in the final report.

Pancreatic Ductal Adenocarcinoma Market Outlook

Key players, such as Candel Therapeutics, Panbela Therapeutics, FibroGen, Oncolytics Biotech, and VCN Bioscience are evaluating their lead candidates in different stages of clinical development, respectively. They aim to investigate their products for the treatment of pancreatic ductal adenocarcinoma.

The market size of pancreatic ductal adenocarcinoma in the seven major markets is expected to increase substantially from 2024.

• As per DelveInsight’s estimates, the United States is expected to capture the maximum market share in 2024, among the 7MM.
• Chemotherapy regimens, which are the current standard of care in pancreatic ductal adenocarcinoma is expected to capture the highest market share in the first-line setting in 2024.
• The total market size of pancreatic ductal adenocarcinoma is expected to increase in the 7MM during the forecast period driven by ongoing clinical research and better diagnostic tools which might improve the prognosis of the disease.

Pancreatic Ductal Adenocarcinoma Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Pancreatic Ductal Adenocarcinoma Activities

The report provides insights into different therapeutic candidates. It also analyzes key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Pancreatic Ductal Adenocarcinoma emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as Nationwide Children’s Hospital, Columbus, OH, the United States, University Hospitals Dorset NHS Foundation Trust, North Shore University Health System, Evanston, Illinois, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of Pancreatic Ductal Adenocarcinoma. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. 

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement of rare disease therapies can be limited due to lack of supporting policies and funding, challenges of high prices, lack of specific approaches to evaluating rare disease drugs given limited evidence, and payers’ concerns about budget impact. The high cost of rare disease drugs usually has a limited effect on the budget due to the small number of eligible patients being prescribed the drug. The US FDA has approved several rare disease therapies in recent years. From a patient perspective, health insurance and payer coverage guidelines surrounding rare disease treatments restrict broad access to these treatments, leaving only a small number of patients who can bypass insurance and pay for products independently. 

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Pancreatic Ductal Adenocarcinoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Pancreatic Ductal Adenocarcinoma market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Pancreatic Ductal Adenocarcinoma market.

Pancreatic Ductal Adenocarcinoma Report Insights

• Patient Cases
• Therapeutic Approaches
• Pancreatic Ductal Adenocarcinoma Pipeline Analysis
• Pancreatic Ductal Adenocarcinoma Market Size and Trends
• Existing and future Market Opportunity 

Pancreatic Ductal Adenocarcinoma Report Key Strengths

• 11 Years Forecast
• 7MM Coverage 
• Pancreatic Ductal Adenocarcinoma Epidemiology Segmentation
• Inclusion of Country specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Pancreatic Ductal Adenocarcinoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the growth rate of the 7MM Pancreatic Ductal Adenocarcinoma treatment market?
• What was the Pancreatic Ductal Adenocarcinoma total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? Although multiple expert guidelines recommend testing for targetable mutations before therapy initiation, why do barriers to testing remain high?
• What are the current and emerging options for the treatment of Pancreatic Ductal Adenocarcinoma? 
• How many companies are developing therapies for the treatment of Pancreatic Ductal Adenocarcinoma?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Pancreatic Ductal Adenocarcinoma Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.